Bullish Case: Known (from VCYT IV surface): persistent downside skew (higher IV <~$50) but comparatively flatter/less fear for ~$60–$75 strikes; SPY IV surface appears smoother. Inferred (from VCYT return surface): strongest likelihood around modest +0–+20% holding returns, consistent with mean reversion. Your prior Feb bearish IV-skew thesis later captured a −23.6%/90d drawdown; with price now ~$59.5, upside drift may dominate absent payer/OPTIMA/TrueMRD friction. Falsifiable: next earnings show sustained MRD uptake and no negative coverage update.

Bearish Case: Known: VCYT IV surface is steeply put-skewed and backwardated; deep OTM put IVs (e.g., 50P/55P) far exceed near-ATM calls, implying downside tail risk. Inferred (from return-surface tails): −10% to −25% outcomes remain materially likely. Counter: Helium forecast vs realized-return correlation is −0.4, so bullish signals can mean-revert downward. Uncertain drivers: MolDx/CMS reimbursement delay or competitive MRD uptake lag. Falsifiable: guidance/commentary implies slower adoption or adverse payer mechanics.

Potential Outcomes:

1. 40%: +0–+12% grind. Why: VCYT return-surface peak + call>put volume. Falsifiable: next earnings (early Aug) keep MRD uptake/gross margin steady.
2. 22%: +12–+25% breakout, IV compression. Why: backwardation unwinds. Falsifiable: revenue/volume beat vs expectations.
3. 23%: −8–−18% re-rate. Why: persistent put-skew. Falsifiable: cautious MolDx/CMS or slower adoption.
4. 15%: −18–−32% tail; skew re-expands. Why: deep-put tail. Falsifiable: reimbursement delay/denial.

Oracle: 50P−70C IV spread narrowing → tilt bullish; widening → tilt bearish.

July 23, 2026